A rare case of centronuclear myopathy with DNM2 mutation: genotype–phenotype correlation by Aghbolaghi, Amir Ghorbani & Lechpammer, Mirna
Autopsy and Case Reports. ISSN 2236-1960. Copyright © 2017. This is an Open Access article distributed 
under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted 
non-commercial use, distribution, and reproduction in any medium provided the article is properly cited.
a University of California, Davis Medical Center, Department of Pathology and Laboratory Medicine. Sacramento, CA, USA.
A rare case of centronuclear myopathy with DNM2 mutation: 
genotype–phenotype correlation
Amir Ghorbani Aghbolaghia, Mirna Lechpammera
How to cite: Ghorbani Aghbolaghi A, Lechpammer M. A rare case of centronuclear myopathy with DNM2 mutation: 
genotype–phenotype correlation. Autops Case Rep [Internet]. 2017;7(2):43-48. http://dx.doi.org/10.4322/acr.2017.020
Article / Clinical Case Report
ABSTRACT
Centronuclear myopathy (CNM) is a group of rare genetic muscle disorders characterized by muscle fibers with centrally 
located nuclei. The most common forms of CNM have been attributed to X-linked recessive mutations in the MTM1 
gene; autosomal-dominant mutations in the DNM2 gene-encoding dynamin-2, the BIN1 gene; and autosomal-recessive 
mutations in BIN1, RYR1, and TTN genes. Dominant CNM due to DNM2 mutations usually follows a mild clinical course 
with the onset in adolescence. Currently, around 35 mutations of the DNM2 gene have been identified in CNM; however, 
the underlying molecular mechanism of DNM2 mutation in the pathology of CNM remains elusive, and the standard 
clinical characteristics have not yet been defined. Here, we describe the case of a 17-year-old female who presented 
with proximal muscle weakness along with congenital anomalous pulmonary venous connection (which has not been 
described in previous cases of CNM), scoliosis, and lung disease without a significant family history. Her creatine kinase 
level was normal. Histology, special stains, and electron microscope findings on her skeletal muscle biopsy showed CNM 
with the characteristic features of a DNM2 mutation, which was later confirmed by next-generation sequencing. This case 
expands the known clinical and pathological findings of CNM with DNM2 gene mutation. 
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INTRODUCTION
Centronuclear myopathy (CNM) is a rare congenital 
myopathy, which was first described as myotubular 
myopathy by Spiro et al.1 in 1966. The muscle biopsy 
is characterized by myofibers with centrally placed 
nucleoli, which are reminiscent of the myotube stage 
of muscle development. The authors suggested that it 
originated from an arrested maturation of embryonic 
muscle. Hence, the condition was called myotubular 
myopathy. It remains unclear if muscle development 
was arrested; therefore the term “centronuclear 
myopathies” was preferred, especially for the late 
onset forms. The term “myotubular” is now used to 
denote severe infantile cases, and reserve CNM denotes 
clinically milder cases affecting older patients in whom 
the muscle biopsy tends to appear “more mature.”2-4
CNM is usually caused by a mutation in the 
myotubularin (MTM1), amphiphysin 2 (BIN1), and 
dynamin 2 (DNM2) genes, which are involved in 
membrane remodeling and trafficking, suggesting 
a common CNM pathophysiology.5 In addition to 
CNM, dissimilar DNM2 mutations are associated with 
Charcot–Marie–Tooth (CMT) peripheral neuropathy 
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(CMTD1B and CMT2M), indicating a tissue-specific 
impact of the mutations. Defects in membrane 
trafficking due to DNM2 mutations potentially 
represent a common pathological mechanism in CNM 
and CMT.6
Three main forms of CNM are recognized 
according to the mode of inheritance and clinical 
presentation7 (Table 1):
1.  X-linked myotubular myopathy (XLMTM): This form 
of CNM is the most severe and the most commonly 
diagnosed type, which is caused by a mutation in the 
MTM1 gene located at Xq27-q28.4,8 Almost all cases 
occur in males and present with severe hypotonia, 
which frequently causes respiratory failure at birth. 
Facial weakness, ptosis, and extraocular muscle weakness 
are common. Rarely, abnormal genital development 
occurs.9 Heterozygous female carriers may present with 
limb girdle and facial weakness.10 Mutations in MTM1 
have also been recognized as the underlying cause 
of atypical forms of XLMTM in newborn boys, female 
infants, and adult men and women, which presents a 
histological alteration in some muscle fibers that resemble 
a necklace (“necklace fibers”).11 Muscle biopsies from 
XLMTM patients show numerous fibers with central nuclei 
resembling myotubes, which are frequently surrounded 
by a paler peripheral halo. These perinuclear paler halos 
are due to mitochondria aggregates, glycogen granules, 
and a reduction in myofilaments.12,13
2.  Autosomal recessive CNM (ARCNM): This form 
presents with relatively mild weakness that may be 
unrecognized in the neonatal period. It is caused by 
mutations in the bridging integrator 1 gene (BIN1).14,15 
Mutations in the RYR1 gene have also been described 
in patients with congenital myopathy with central nuclei, 
although it is now recognized that these patients have a 
form of RYR1-related congenital myopathy rather than 
CNM.16,17 Recessive mutations in TTN that encode the giant 
sarcomeric ruler protein, titin, have also been identified in 
some patients with congenital myopathies with central 
nuclei.18 The muscle biopsies in BIN1-related CNM show 
a large majority of rounded fibers with centralized nuclei 
and an increased amount of endomysial fibrosis; some 
fibers have clusters of centrally placed nuclei on H&E 
staining. The presence or absence of ophthalmoparesis 
in early onset cases has been suggested as a means to 
clinically classify ARCNM into three subgroups:19 (i) early 
onset with ophthalmoparesis: patients tend to be more 
severely affected and may present with dysmorphic 
features; (ii) early onset without ophthalmoparesis; 
and (iii) late onset without ophthalmoparesis: affected 
patients have a clinical phenotype similar to patients with 
autosomal dominant CNM.
3. Autosomal dominant CNM (ADCNM): This disorder 
not only involves mainly limb girdle, trunk, and neck 
muscles, but also it may affect the distal muscles. 
Weakness may not become evident until the third decade 
of life. It is caused by a mutation in dynamin 2 (DNM2) on 
chromosome 19.20 The most prominent histopathological 
features include the frequency of centrally located nuclei 
Table 1. Centronuclear myopathies
Centronuclear myopathy Mutation Clinical presentation Microscopic features
XLMTM MTM1 gene (Xq28)
Usually males, hypotonia, 
respiratory failure at birth, 
facial weakness, ptosis, and 
extraocular muscle weakness
Fibers with central nuclei 
resembling myotubes, which 
are frequently surrounded 
by a paler peripheral halo
Heterozygous female carriers 
may present with limb girdle 
and facial weakness




Early onset with 
ophthalmoparesis: tend to 
be more severely affected 
and may present with 
dysmorphic features
Large majority of rounded 
fibers with centralized 
nuclei and an increase of 
endomysial fibrosis; some 
fibers have clusters of 
centrally placed nuclei
RYR1 gene (19q13.2) Early onset without ophthalmoparesis
TTN gene (2q31.2)
Late onset without 
ophthalmoparesis: (similar to 
ADCNM)
ADCNM DNM2 gene (19p13.2)
Classic form: it is 
characterized by late onset 
(may present in the patient’s 
30s) and slow progression
Numerous fibers with 
centrally located nuclei 
and sarcoplasmic strands 
radiating from the central 
nucleus (“spoke-like 
appearance”), hypotrophy 
of type 1 fibers
With muscle hypertrophy: it 
presents at a younger age 
with a more rapid course
ADCNM = autosomal dominant centronuclear myopathy; ARCNM = autosomal recessive centronuclear myopathy; 
XLMTM = X-linked myotubular myopathy.
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in a large number of the extrafusal muscle fibers, the 
radial arrangement of sarcoplasmic strands around the 
central nuclei, and the predominance and hypotrophy of 
type 1 fibers. ADCNM can be divided to two subgroups 
due to the presence or absence of muscle hypertrophy:19 
(i) classic form: this is characterized by late onset and slow 
progression; and (ii) with muscle hypertrophy: this usually 
presents at a younger age and has a more rapid course.
CASE REPORT
A 17-year-old Caucasian female with a past 
medical history of anomalous pulmonary venous 
connection (left to right shunt), biphasic thoracolumbar 
scoliosis, and restrictive lung disease, presented 
with progressive proximal muscle weakness and 
lumbar pain. There was no specific family history of 
neurological disease. Upon physical examination, we 
observed levoscoliosis and weakness in the bilateral 
upper extremities (4/5) and the lower extremities (3/5). 
She was unable to walk on her toes or heels, and was 
unable to arise from a squatting position, although 
her gait was not grossly abnormal on observation. 
There was no facial weakness, and her extraocular 
movements were intact. Sensory examination showed 
intact sensation bilaterally. There was no spasticity, 
Babinski sign, or ankle clonus.
An x-ray showed scoliosis and kyphoscoliosis. 
Magnetic resonance imaging findings were suggestive 
of paraspinal muscle edema suspicious for an 
underlying myopathy process. A partial anomalous 
pulmonary venous return with left to right shunt was 
also observed. An electromyography (EMG) showed 
electrodiagnostic evidence of diffuse myopathic 
process. The creatine kinase (CK) level was normal: 
68 (reference range: 0-250 U/L).
The microscopic examination of the muscle 
biopsy (left vastus lateralis) showed excess variability 
in fiber size (Figure 1A), and frequent myonuclei in 
the center of the muscle fibers (Figure 1B), which 
often formed chains when viewed longitudinally 
(Figure 1C). Degenerating fibers, angulated, split fibers, 
and nuclear bags were not present. Myophagocytosis 
was not present, and inflammatory infiltrates were 
not seen. Rare fibers contained central red stippling; 
however, definitive ragged red fibers were not seen. 
NADH histochemistry showed increased reaction in 
Figure 1. Photomicrography of the muscle biopsy. A - Fiber size variation and centralized nuclei especially in small 
fibers (H&E); B - Central nuclei are observed in majority of cells (H&E); C - Centrally located nuclei often forming 
chains in a longitudinal section (H&E); D - Radial arrangement of inter-myofibrillar network (spoke-like appearance) 
(NADH stain).
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the center of some fibers with radial arrangement 
of the intermyofibrillar network radiating from the 
central nucleus (a spoke-like appearance on the fibers) 
(Figure 1D).
ATPase (pH 9.8, 4.6, 4.3) histochemical stains 
show type I fiber predominating (more than 90%), and 
type II fibers were normal in size or were hypertrophic 
(Figure 2A). Electron microscopy with toluidine blue 
staining showed disruption of myofibers particularly 
around the central nuclei (Figure 2B). Glycogen content 
appeared mildly increased in areas, and scattered 
collections of mitochondria and occasional nonspecific 
inclusions were noted.
Mitochondrial DNA (mtDNA) whole genome 
sequencing was performed at a third-party lab (using the 
internal guidelines at the Medical Neurogenetic Lab, 
State of Georgia license #044-146) and showed a 
heterozygous missense variant in exon 11 of the 
DNM2 gene located on chromosome 19; DNM2 
(NM_001005360.2):c.1393C>T: p.Arg465Trp. 
This variant corresponded to the SNP rs121909091 
and had been observed previously in at least three 
individuals with CNM, according to the ClinVar 
database. It is not found in more than 60,000 controls 
in the ExAC database.21
DISCUSSION
CNM is a rare congenital myopathy, which can 
be diagnosed based on histology. Three forms of 
the disease are clinically recognized: (i) the X-linked 
severe neonatal form, which is caused by MTM1 
mutation; (ii) the autosomal recessive childhood onset 
form, which is usually caused by BIN1 mutation; and 
(iii) the autosomal dominant adult-onset form, which 
is caused by DNM2 mutation. Genotype–phenotype 
correlation hypotheses are drawn from published 
and new data and allow an efficient screening 
strategy for molecular diagnosis. Here, we report the 
clinical, pathological, and molecular characteristics 
of a 17-year-old patient with DNM2-related CNM, 
which was confirmed by genetic testing. The patient 
presented with muscle weakness and associated 
disabilities (thoracolumbar scoliosis with restrictive 
lung disease), as well as anomalous pulmonary venous 
connection. Because the cardiac abnormality has not 
been described in patients with DNM2-related CNM, 
it is not clear whether it could be just a co-occurrence 
condition or the first description of this new finding. 
Therefore, more evidence is needed to conclude this 
matter. The laboratory work-up showed normal blood 
CK levels; however, the EMG study was consistent with 
myopathy. The microscopic and histochemistry studies 
of the muscle biopsy showed radial oxidative staining 
of sarcoplasmic strands (on NADH staining) and type I 
muscle fiber predominance with type II muscle fiber 
hypertrophy (on ATPase staining), which was suggestive 
of DNM2-related changes. A further genetic work-up 
revealed a DNM2 mutation on chromosome 19, and 
confirmed the diagnosis of ADCNM.
Figure 2. Photomicrography of the muscle biopsy. A - ATPase (pH 4.3) type II fiber hypertrophy and type I fiber 
predominance (>90%); B - Electronic microscopy: fibers with central nuclei and radial sarcoplasmic strands (X 6300).
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